Dersalazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dersalazine
Accession Number
DB06251
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
UR-12746
Product Ingredients
IngredientUNIICASInChI Key
Dersalazine SodiumBAB844203H367249-56-7YLEYSRAGECECMB-UUHDFEAYSA-M
Categories
UNII
WS1IH75AJT
CAS number
188913-58-8
Weight
Average: 600.679
Monoisotopic: 600.248503534
Chemical Formula
C35H32N6O4
InChI Key
AYEAMZDTWLXZIJ-RKOUKRECSA-N
InChI
InChI=1S/C35H32N6O4/c1-23-37-31-21-36-16-13-32(31)41(23)22-24-14-17-40(18-15-24)34(43)20-29(25-5-3-2-4-6-25)26-7-9-27(10-8-26)38-39-28-11-12-33(42)30(19-28)35(44)45/h2-13,16,19-21,24,42H,14-15,17-18,22H2,1H3,(H,44,45)/b29-20-,39-38+
IUPAC Name
2-hydroxy-5-[(E)-2-{4-[(1Z)-3-[4-({2-methyl-1H-imidazo[4,5-c]pyridin-1-yl}methyl)piperidin-1-yl]-3-oxo-1-phenylprop-1-en-1-yl]phenyl}diazen-1-yl]benzoic acid
SMILES
CC1=NC2=CN=CC=C2N1CC1CCN(CC1)C(=O)\C=C(\C1=CC=CC=C1)C1=CC=C(C=C1)\N=N\C1=CC(C(O)=O)=C(O)C=C1

Pharmacology

Indication

Investigated for use/treatment in inflammatory bowel disease.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Dersalazine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Dersalazine is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Dersalazine.Approved
AcarboseDersalazine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolDersalazine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetazolamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dersalazine.Approved, Vet Approved
AlbiglutideDersalazine may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Aldosterone.Experimental, Investigational
AlogliptinDersalazine may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Aloxiprin.Experimental
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Dersalazine.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Amcinonide.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Dersalazine.Approved
Ammonium chlorideThe serum concentration of Dersalazine can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Dersalazine.Approved
AncrodDersalazine may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Dersalazine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Dersalazine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Dersalazine is combined with anecortave acetate.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Anistreplase.Approved
Antithrombin III humanDersalazine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanDersalazine may increase the anticoagulant activities of Apixaban.Approved
ArdeparinDersalazine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Dersalazine.Approved, Investigational
AstaxanthinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Atamestane.Investigational
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dersalazine.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Dersalazine.Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Dersalazine.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Batroxobin.Experimental
BecaplerminDersalazine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Beclomethasone dipropionate.Approved, Investigational
BemiparinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Bemiparin.Approved, Investigational
BenazeprilThe therapeutic efficacy of Benazepril can be decreased when used in combination with Dersalazine.Approved, Investigational
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Dersalazine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Betamethasone.Approved, Vet Approved
BivalirudinDersalazine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Brinzolamide.Approved
BromocriptineDersalazine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Budesonide.Approved
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Dersalazine.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Dersalazine.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Dersalazine.Investigational
CanagliflozinDersalazine may increase the hypoglycemic activities of Canagliflozin.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Dersalazine.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Dersalazine.Approved
CaplacizumabThe risk or severity of adverse effects can be increased when Dersalazine is combined with Caplacizumab.Investigational
CaptoprilThe therapeutic efficacy of Captopril can be decreased when used in combination with Dersalazine.Approved
Carbaspirin calciumDersalazine may increase the anticoagulant activities of Carbaspirin calcium.Experimental, Investigational
CertoparinDersalazine may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlorpropamideDersalazine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Dersalazine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Dersalazine.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Dersalazine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Dersalazine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Clocortolone.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Dersalazine.Approved
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Dersalazine.Experimental
ClorindioneDersalazine may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Cortisone acetate.Approved, Investigational
Dabigatran etexilateDersalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinDersalazine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDersalazine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinDersalazine may increase the hypoglycemic activities of Dapagliflozin.Approved
DarexabanDersalazine may increase the anticoagulant activities of Darexaban.Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Dersalazine.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Dersalazine is combined with Deflazacort.Approved, Investigational
DelaprilThe therapeutic efficacy of Delapril can be decreased when used in combination with Dersalazine.Investigational
DesirudinDersalazine may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dersalazine is combined with Dexketoprofen.Approved, Investigational
DextranDersalazine may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenacThe therapeutic efficacy of Dersalazine can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Diclofenamide.Approved, Investigational
DicoumarolDersalazine may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Dersalazine.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Difluprednate.Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Dersalazine.Approved, Investigational
DiphenadioneDersalazine may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Dersalazine.Approved
DisopyramideDersalazine may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Dorzolamide.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Dersalazine is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DulaglutideDersalazine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
Edetic AcidDersalazine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanDersalazine may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinDersalazine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe therapeutic efficacy of Enalapril can be decreased when used in combination with Dersalazine.Approved, Vet Approved
EnalaprilatThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Dersalazine.Approved
EnoxaparinDersalazine may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Dersalazine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Dersalazine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Dersalazine.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Dersalazine.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Dersalazine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Equilin.Approved
EstroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dersalazine.Approved, Investigational
EthoxzolamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateDersalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideDersalazine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
Ferulic acidDersalazine may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fibrinolysin.Investigational
FluasteroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fludrocortisone.Approved, Investigational
FluindioneDersalazine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Flurandrenolide.Approved
FluticasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluticasone propionate.Approved
FondaparinuxDersalazine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure can be increased when Dersalazine is combined with Fosinopril.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Dersalazine.Approved, Vet Approved
GabexateDersalazine may increase the anticoagulant activities of Gabexate.Investigational
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Dersalazine.Approved, Investigational, Nutraceutical
GliclazideDersalazine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideDersalazine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideDersalazine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideDersalazine may increase the hypoglycemic activities of Glyburide.Approved
GuacetisalDersalazine may increase the anticoagulant activities of Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Halcinonide.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Dersalazine is combined with HE3286.Investigational
Hemoglobin crosfumarilDersalazine may increase the anticoagulant activities of Hemoglobin crosfumaril.Experimental
HeparinDersalazine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dersalazine.Approved, Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Dersalazine.Approved, Investigational
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Dersalazine.Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Dersalazine.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Dersalazine.Approved, Investigational, Nutraceutical
IdraparinuxDersalazine may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Dersalazine.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Dersalazine.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Dersalazine.Approved, Investigational
ImidaprilThe therapeutic efficacy of Imidapril can be decreased when used in combination with Dersalazine.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Dersalazine is combined with Indobufen.Investigational
Insulin AspartDersalazine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirDersalazine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineDersalazine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineDersalazine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanDersalazine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproDersalazine may increase the hypoglycemic activities of Insulin Lispro.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Dersalazine is combined with Istaroxime.Investigational
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Dersalazine.Investigational
KetorolacThe therapeutic efficacy of Dersalazine can be decreased when used in combination with Ketorolac.Approved
LepirudinDersalazine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanDersalazine may increase the anticoagulant activities of Letaxaban.Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Dersalazine.Experimental
LiraglutideDersalazine may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Dersalazine.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Dersalazine is combined with Loteprednol.Approved
ME-609The risk or severity of adverse effects can be increased when Dersalazine is combined with ME-609.Investigational
MecaserminDersalazine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Medrysone.Approved
MelagatranDersalazine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Dersalazine is combined with Melengestrol.Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Dersalazine.Approved
MetforminDersalazine may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Dersalazine is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dersalazine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Dersalazine.Approved
Methyl salicylateThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Dersalazine is combined with Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Methylprednisolone.Approved, Vet Approved
MifepristoneDersalazine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolDersalazine may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Dersalazine.Approved
MoexiprilThe therapeutic efficacy of Moexipril can be decreased when used in combination with Dersalazine.Approved
MometasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Mometasone.Approved, Vet Approved
NadroparinDersalazine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatDersalazine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Dersalazine.Investigational
NaproxenThe therapeutic efficacy of Dersalazine can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideDersalazine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Dersalazine is combined with NCX 1022.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dersalazine.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dersalazine.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Oleoyl-estrone.Investigational
OlsalazineOlsalazine may increase the anticoagulant activities of Dersalazine.Approved
OmapatrilatThe therapeutic efficacy of Omapatrilat can be decreased when used in combination with Dersalazine.Investigational
OtamixabanDersalazine may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ozagrel.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Paramethasone.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateDersalazine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineDersalazine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Pentosan PolysulfateDersalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Dersalazine.Approved, Investigational
PerindoprilThe therapeutic efficacy of Perindopril can be decreased when used in combination with Dersalazine.Approved
PhenindioneDersalazine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonDersalazine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateDersalazine may increase the anticoagulant activities of Phenyl aminosalicylate.Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Dersalazine.Experimental
PioglitazoneDersalazine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Dersalazine.Approved
Potassium CitrateDersalazine may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Dersalazine.Approved, Investigational
PramlintideDersalazine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Dersalazine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Dersalazine.Approved, Investigational
Protein CDersalazine may increase the anticoagulant activities of Protein C.Approved
Protein S humanDersalazine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDersalazine may increase the anticoagulant activities of Protocatechualdehyde.Approved
QuinaprilThe therapeutic efficacy of Quinapril can be decreased when used in combination with Dersalazine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Dersalazine.Approved
QuinineDersalazine may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Dersalazine.Investigational
RamiprilThe therapeutic efficacy of Ramipril can be decreased when used in combination with Dersalazine.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Dersalazine.Investigational
RepaglinideDersalazine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Dersalazine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dersalazine.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Reteplase.Approved, Investigational
ReviparinDersalazine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Dersalazine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Rimexolone.Approved
RivaroxabanDersalazine may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneDersalazine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Salicylic acid is combined with Dersalazine.Approved, Investigational, Vet Approved
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Dersalazine.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Saruplase.Experimental
SaxagliptinDersalazine may increase the hypoglycemic activities of Saxagliptin.Approved
SelexipagThe risk or severity of adverse effects can be increased when Dersalazine is combined with Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dersalazine.Approved, Vet Approved
SitagliptinDersalazine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium CitrateThe risk or severity of bleeding can be increased when Dersalazine is combined with Sodium Citrate.Approved, Investigational
SpiraprilThe therapeutic efficacy of Spirapril can be decreased when used in combination with Dersalazine.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Dersalazine.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Streptokinase.Approved, Investigational
SulfadiazineDersalazine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleDersalazine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Sulfasalazine is combined with Dersalazine.Approved
SulfisoxazoleDersalazine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe therapeutic efficacy of Dersalazine can be decreased when used in combination with Sulindac.Approved, Investigational
SulodexideDersalazine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SunitinibDersalazine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TemocaprilThe therapeutic efficacy of Temocapril can be decreased when used in combination with Dersalazine.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Tenecteplase.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Dersalazine.Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Dersalazine.Approved
TinzaparinThe risk or severity of adverse effects can be increased when Dersalazine is combined with Tinzaparin.Approved
TioclomarolDersalazine may increase the anticoagulant activities of Tioclomarol.Experimental
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Dersalazine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Dersalazine is combined with Tixocortol.Approved, Withdrawn
TolazamideDersalazine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideDersalazine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Dersalazine.Approved
TrandolaprilThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Dersalazine.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Dersalazine.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Dersalazine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Dersalazine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Dersalazine is combined with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Dersalazine.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Dersalazine.Approved, Investigational
Trolamine salicylateThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Dersalazine is combined with Trolamine salicylate.Approved
TroxerutinDersalazine may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ulobetasol.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Dersalazine is combined with Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Dersalazine.Approved, Investigational
VerapamilVerapamil may increase the anticoagulant activities of Dersalazine.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Dersalazine.Approved
WarfarinDersalazine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDersalazine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZofenoprilThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Dersalazine.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
20158304

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentUlcerative Colitis (UC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00415 mg/mLALOGPS
logP6.2ALOGPS
logP5.14ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)3.23ChemAxon
pKa (Strongest Basic)5.56ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area133.27 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity184.21 m3·mol-1ChemAxon
Polarizability65.09 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:19 / Updated on August 02, 2018 05:35